Press Release

AveXis – $169 Million Follow-On Offering

September 21, 2016

New York – September 21, 2016 – Cooley advised AveXis and a selling stockholder on their recent $168.9 million primary/secondary offering of an aggregate of 4,887,500 shares of common stock.

AveXis, which trades on The NASDAQ Global Select Market, is a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases.

Cooley also advised AveXis on its IPO earlier this year.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.